

DUPIXENT® (dupilumab) receives positive recommendation from CADTH for moderate-to-severe atopic dermatitis

- Recommendation supported by multiple clinical trials that demonstrated superiority of Dupixent® over placebo in improving disease extent and severity, skin clearance and itch intensity, as well as health-related quality of life
- First and only biologic approved in Canada for patients aged 12 and above with moderate-to-severe atopic dermatitis

MISSISSAUGA, ON – April 24, 2020– Sanofi Canada is pleased to announce the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) issued a recommendation that DUPIXENT® (dupilumab) be reimbursed by public drug plans for Canadians aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately managed with current therapy and when specific conditions are met. Full details on the recommendation by CDEC, including recommended criteria for reimbursement, are available on the [CADTH website](#).

“The recommendation from CADTH is a positive step forward for Canadians living with the significant burden of atopic dermatitis,” said Marissa Poole, General Manager, Sanofi Genzyme Canada. *“Expanded access to DUPIXENT® through public programs helps address a distinct unmet patient need, and we look forward to continuing to work with provincial and territorial governments to make the treatment available to more Canadians who need it.”*

DUPIXENT® is reimbursed by the Régie de l'assurance maladie Québec (RAMQ), in Quebec and by the Non-Insured Health Benefits (NIHB) program for patients over the age of 18 with moderate to severe atopic dermatitis. It is currently under review with the *Institut national d'excellence en santé et en services sociaux*(INESSS) for the treatment of moderate-to-severe atopic dermatitis for adolescents aged 12 to 18 years. DUPIXENT® is also covered by many private insurance programs in Canada for adults and adolescents with moderate-to-severe atopic dermatitis.

Atopic dermatitis (AD), the most common form of eczema, is a chronic inflammatory disease. In its moderate-to-severe form, it is characterized by rashes that can potentially cover much of the body, and can include intense, persistent itching, skin lesions and skin dryness, cracking redness, crusting and oozing. Inadequately controlled atopic dermatitis can have a physical, emotional and psychosocial impact, causing sleep disturbance, symptoms of anxiety and depression, and feelings of isolation.

About DUPIXENT®: Innovative Treatment for Patients with Moderate-to-Severe Atopic Dermatitis

DUPIXENT® is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.

DUPIXENT®, was first approved by Health Canada on November 30, 2017 for the treatment of adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In September, 2019, Health Canada expanded the approval to include adolescents aged 12 years and older.

DUPIXENT® is jointly developed by Sanofi and Regeneron under a global collaboration agreement.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi entities in Canada employ approximately 2,000 people. In 2018, we invested more than \$127 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

Follow us on Twitter @SanofiCanada and on YouTube.

Sanofi, Empowering Life

For further information: Marissa Smith, Tel: +1 (416) 892-2158, Marissa.Smith@sanofi.com
